Oxford Nanopore Technologies PLC
Company Profile
Business description
Oxford Nanopore Technologies PLC makes a novel generation of DNA/RNA sequencing technology that provides rich data and is fast, accessible, and easy to use. The company is predominantly involved in researching, developing, manufacturing, and commercializing a nanopore-based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). This enables its customers to perform scientific/biomedical research in a range of areas, including human genetics, cancer research, outbreak surveillance, environmental analysis, pathogens/antimicrobial resistance, microbiome analysis, and crop science. The company's reportable segments are; Life Science Research Tools which generates key revenue, and COVID Testing.
Contact
Edmund Halley Road
Gosling Building, Oxford Science Park
OxfordOxfordshireOX4 4DQ
GBRT: +44 8450347900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,315
Stocks News & Analysis
stocks
ASX reporting season wrap: BHP, banks, CSL bloodbath and more
stocks
Stock showdown: How do ASX healthcare giants compare on key investing criteria?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,234.30 | 55.70 | -0.60% |
CAC 40 | 7,969.69 | 31.40 | 0.40% |
DAX 40 | 24,363.09 | 69.75 | 0.29% |
Dow JONES (US) | 45,631.74 | 846.24 | 1.89% |
FTSE 100 | 9,321.40 | 12.20 | 0.13% |
HKSE | 25,339.14 | 234.53 | 0.93% |
NASDAQ | 21,496.54 | 396.22 | 1.88% |
Nikkei 225 | 42,633.29 | 23.12 | 0.05% |
NZX 50 Index | 13,119.39 | 76.63 | 0.59% |
S&P 500 | 6,466.91 | 96.74 | 1.52% |
S&P/ASX 200 | 8,967.40 | 57.00 | -0.63% |
SSE Composite Index | 3,825.76 | 54.66 | 1.45% |